Alzheimers Disease Market analysis and forecasts, 2007-2022

Questions: Discounts, Updates etc.

Price (Single): £1499

Price (Departmental): £2999

Price (Company): £4999

Publication Date: 2007-11-01

Order Online Now

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Alzheimers disease is the third leading cause of death in recent times and with an unprecedented patient potential, this disease area attracts awareness from a broad base of stakeholders. With the grey population being the single most influencial factor in driving the economic growth within this sector, the authors of Alzheimer's Disease Market analysis and forecasts highlight how the real market of the Alzheimers disease industry still remains untapped.

Over the past decade the Alzheimers disease market has been flagged by a quartet of approved pharmacological agents; acetyl cholinesterase inhibitors (AchEIs), N-methyl D-aspartate (NMDA) receptor antagonists and other non-Alzheimers disease specific therapeutics for management of comorbidities. The AchEIs comprise products from some of the leading larger pharmaceutical companies;

However, all the listed drugs only elicited modest clinical benefits in treating the various stages of the Alzheimers disease. In addition, the UK National Institute of Clinical Excellence (NICE) decision not to place the drugs on the NHS for reimbursement generated major controversy across the larger markets, only to affect the potential revenue growth on the major drugs particularly in the UK, one of the significant markets.

What questions does the report answer?

Revenues of the only approved Alzheimers disease drugs across the major markets (US, Japan, France, Germany, Italy, Spain and the UK) totaled over $3 billion in 2006, with revenues expected to exceed $5 billion by 2012. By 2014, Visiongain anticipates that, all the Alzheimers disease approved therapies will come of patents in the major markets signaling a potential genericisation of the Alzheimers disease market.

With looming patient potential over the major products, Visiongain's market analysis forecast a-to- be lucrative era during the mid-term of our forecast where we believe, the sector will see the penetration of highly innovative Alzheimers disease products presently in late-phase clinical studies into the Alzheimers disease arena, only heralded by modest therapies, as opposed to the large outcry for highly effective drugs complimented by value for money by inter-country healthcare regulatory authorities.

With country-by-country focus on the markets of:

This report includes detailed five-year forecasts over the period 2007-2012, and aswell as 10 and 15 year forecasts to help you understand the medium-term prospects for these markets.

Table of Contents

Other users found this report page using the following search terms: Alzheimer's disease neurodegeneration neurodegenerative alzheimers market disease aricept 2007 sales analysis share drugs prevalence

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.